Bausch + Lomb announced that it has filed a registration statement with the U.S. Securities and Exchange Commission to take the company public.
Bausch + Lomb named Robert Bertolini as president and CFO effective immediately.
Bausch & Lomb is actively exploring a sale that could command upward of $10 billion, according to a report in The Wall Street Journal published Tuesday.
Bausch + Lomb will acquire eye drug maker Ista Pharmaceuticals for $9.10 per share in cash, or approximately $500 million.
Bausch + Lomb on Friday appointed a clinical professor of ophthalmology to serve as the company's first-ever chief medical officer.